Treatment of Graft-Versus-Host Disease Disorders using RAR Antagonists
AssigneesIo Therapeutics, Inc., Regents of the University of Minnesota
InventorsBruce Blazer, Kazutoshi Aoyama, Roshantha Chandraratna
Life of this patent
Estimating the term…
Abstract
The present specification provides RAR antagonist compounds, compositions comprising such RAR antagonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RAR antagonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
Claims20
A method of treating a transplant rejection, the method comprising administering to an individual in need thereof a therapeutically effective amount of a RAR antagonist, thereby treating the transplant rejection in the individual.
A method of treating graft-versus-host disease, the method comprising administering to an individual in need thereof a therapeutically effective amount of a RAR antagonist, thereby treating the graft-versus-host disease in the individual.
Dependencies are inferred from the claim text.